Covalent inhibitors for drug discovery
Category
Research Platforms
Register type
Biotech Sanitaria
Company name
Product / Service
Covalent inhibitors for drug discovery
Type
CRO
Enabling Technologies
Screening/Drug Discovery
Properties/Indication
In collaboration with Melius Organics and OTAVA Chemicals, a library of 74,543 SuFEx fragments was created. These fragments support efficient, mild, high-yield linkages using unique S(VI)–F bond reactivity.
Application
SuFEx is a next-gen method for covalent drug discovery, enabling the formation of new covalent bonds using amino acids like lysine, tyrosine, and histidine. It's ideal for designing covalent warheads, enzyme profiling, and protein conjugation.
Development phase
Registration
Commercialized
✔
Market release year
2025